 | Up a level |
Al-Batran, S-E., Hofheinz, R. D., Schmalenberg, H., Strumberg, D., Goekkurt, E., Angermeier, S., Zander, T., Potenberg, J., Kopp, H-G., Pink, D., Siegler, G. M., Schenk, M., De Vita, F., Maiello, E., Gaiser, T., Sookthai, D., Bankstahl, U. S., Pauligk, C., Goetze, T. O. and Homann, N. (2020). Perioperative FLOT plus ramucirumab versus FLOT alone for resectable esophagogastric adenocarcinoma- Updated results and subgroup analyses of the randomized phase II/III trial RAMSES/FLOT7 of the German AIO and Italian GOIM. Ann. Oncol., 31. S. S901 - 1. AMSTERDAM: ELSEVIER. ISSN 1569-8041
Gotze, T. O., Al-Batran, S-E, Bankstahl, U. S., Fleckenstein, A-S, Engel, J. B., Aktas, B., Martin, M., Weisgerber, C., Hunold, P., Gallwas, J., Kulenkampff, D., Maintz, D., Morgenstern, B., Puesken, M., Keim, S., Matzko, M. and Duex, M. (2022). Multicentric, randomized Phase III Trial of Magnetic Resonance Imaging-guided highly focused Ultrasound Therapy for the Treatment of Uterine Fibroid (MRgFUS-TUF) Patients versus Myomectomy for symptomatic and drug-naive Uterine Fibroid (MARGI-T) Patients. Geburtshilfe Frauenheilkd., 82 (10). S. E73 - 2. STUTTGART: GEORG THIEME VERLAG KG. ISSN 1438-8804